The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Controversies surrounding the management and treatment of lymphomas
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, shares some insights into the controversies surrounding the management of lymphomas, drawing focus on the numerous studies being conducted and how treatment practices are quickly changing. Dr Nastoupil highlights some of the novel therapies being made available, including CAR-T and bispecific antibodies, and the challenges that clinicians face with interpreting this novel data and ensuring that the best treatment decisions are made for each lymphoma sub-type. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
